fulvestrant teva 250 mg solution for injection in pre-filled syringe
teva b.v. - fulvestrant - solution for injection in pre-filled syringe - 250 milligram(s) - anti-estrogens; fulvestrant
fulvestrant teva solution for injection 250mg
teva b.v. swensweg 5, 2031 ga haarlem, netherlands - fulvestrant - solution for injection in a pre-filled syringe - fulvestrant 250 mg - endocrine therapy
fulvestrant teva
teva israel ltd - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapyfulvestrant teva is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy, or* with disease progression on endocrine therapy.combination therapyfulvestrant teva is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
fulvestrant-teva solution for injection 250mg5ml
teva pharmaceutical investments singapore pte. ltd. - fulvestrant - injection, solution - fulvestrant 250 mg/5ml
fulvestrant teva 250 mg inj. sol. i.m. pre-filled syr.
teva pharma belgium sa-nv - fulvestrant 250 mg/5 ml - solution for injection in pre-filled syringe - 250 mg - fulvestrant 50 mg/ml - fulvestrant
teva-fulvestrant injection solution
teva canada limited - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents
fulvestrant sandoz
novartis israel ltd - fulvestrant - solution for injection - fulvestrant 50 mg/ml - fulvestrant - monotherapyfulvestrant sandoz® is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:- not previously treated with endocrine therapy, or - with disease relapse on or after adjuvant endocrine therapy; or - disease progression on endocrine therapycombination therapy with palbociclibfulvestrant sandoz® is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
fulvestrant ever pharma fulvestrant 250 mg/5 ml solution for injection pre-filled syringe
interpharma pty ltd - fulvestrant, quantity: 50 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; benzyl benzoate; castor oil; ethanol - fulvestrant ever pharma is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2(her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant accord fulvestrant 250 mg/5 ml solution for injection pre-filled syringe
accord healthcare pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: benzyl alcohol; castor oil; benzyl benzoate; ethanol - fulvestrant accord is indicated for the treatment of postmenopausal women with: ? hormone-receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. ? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.
fulvestrant-aft fulvestrant 250 mg/5 ml solution for injection pre-filled syringe
aft pharmaceuticals pty ltd - fulvestrant, quantity: 250 mg - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - fulvestrant-aft is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.